PUBLISHER: IMARC | PRODUCT CODE: 1820077
PUBLISHER: IMARC | PRODUCT CODE: 1820077
The global safety needles market size reached USD 3.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.4 Billion by 2033, exhibiting a growth rate (CAGR) of 8.6% during 2025-2033.
Safety needles are used to deliver drugs, collect fluids from the body, and prevent the spread of needlestick injuries or infections associated with healthcare provision. They protect healthcare workers and patients from bloodborne pathogens and hazardous drug exposure. Some of the widely available safety needles are biopsy, Huber, cannula, pen, suture, prefilled, hypodermic, fine aspirating, intravenous (IV) catheter, blood collection, arteriovenous (AV) fistula, and spinal anesthesia and epidural. Nowadays, automated pen needles with built-in safety features are being introduced to provide various benefits in insulin injection.
Injections are considered a main source of infection in transmitting bloodborne diseases, such as Hepatitis B, D, and C and Human Immunodeficiency Virus (HIV). As a result, health agencies of several countries are implementing laws for safe injection practices, which represents one of the major factors impelling the growth of the market. Safety needles help reduce the incidences of iatrogenic infection and save costs. In addition, they are used to prevent the transmission risk of bloodborne viruses and protect patients from needlestick injuries while administering coronavirus disease (COVID-19) vaccines. Apart from this, due to the growing prevalence of chronic diseases and awareness about the risk associated with filled syringes, there is a rise in the adoption of prefilled syringes across the globe, which, in turn, is driving the market. Moreover, several health firms are introducing needle-based safety devices that can be attached to a conventional or prefilled syringe. Furthermore, initiatives undertaken by governing agencies of numerous countries for needle disposal are projected to aid the market growth. For instance, a program was launched in the City of Bloomington (United States) to install sharps containers in public parks and address the increasing number of used syringes.
The competitive landscape of the industry has also been examined along with the profiles of the key players being B. Braun Melsungen AG, Becton Dickinson and Company, Boston Scientific Corporation, Cardinal Health Inc., Johnson & Johnson, Nipro Corporation, Novo Nordisk A/S, Retractable Technologies Inc., Smiths Group plc, Terumo Corporation and Vygon.